SGM update - Amendment

RNS Number:4388C
Cross Shore Acquisition Corporation
17 August 2007



This announcement replaces the previous RNS announcement released at 14:24 on 17
August 2007 under reference 3685C, which incorrectly stated the SGM date and
proxy deadline dates. The correct SGM date is 28 August 2007 and the time for
receipt of proxies is 8.00am London time on 28 August 2007. There are no other
changes to the announcement. The full corrected text of the announcement appears
below.


Cross Shore Acquisition Corporation

17 August 2007

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE
UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH
  AFRICA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
              VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.


                            Special General Meeting


Cross Shore announces that its Special General Meeting which was adjourned on 10
August 2007 shall be held on 28 August 2007 at 3.00pm Chicago time at the
offices of McDermott Will & Emery LLP, 227 West Monroe Street, Chicago, Illinois
60606. At the meeting Shareholders will be asked to vote on a number of
resolutions related to the acquisition of ReSearch Pharmaceutical Services, Inc.
(the "Acquisition"), as previously set out in the notice of Special General
Meeting sent to Shareholders on 6 July 2007.

As of 10 August 2007, the company had not received sufficient votes to approve
the Acquisition. However, as previously announced, Cross Shore had received
expressions of interest from third party institutional investors who indicated
their interest in acquiring a significant number of shares and warrants which,
if acquired, voted, and tendered respectively, may allow the transaction to
proceed. Therefore, the Board adjourned the meeting on 10 August 2007 to allow
the Company to pursue those discussions. Those discussions have been ongoing and
the Board of Directors reasonably believes that a definitive agreement will be
entered into shortly to allow the transaction to proceed.

Approximately 35.8 million warrants have been tendered pursuant to the warrant
tender offer, an amount in excess of the 95 per cent. required as a condition to
completing the Acquisition. The completion of the warrant tender offer remains
conditional on completion of the Acquisition and absent completion of the
Acquisition, the warrants will not convert into shares and will remain as
warrants. Pending satisfaction of the remaining conditions of the Merger
Agreement, either party is entitled to terminate the Merger Agreement on written
notice to the other.

Proxies already submitted in respect of the Special General Meeting will remain
valid for the adjourned meeting; however, if a shareholder wishes to change
their vote, they should either request and complete a new proxy form, which
should be returned no later than 08.00 a.m. London time on 28 August 2007, or
attend the meeting in person.


ENQUIRIES:

Cross Shore                      [phone]
Dennis Smith

Arbuthnot Securities Limited     [phone]
Nominated Adviser
James Steel / Guy Blakeney


This announcement does not constitute, or form part of, an offer or an
invitation to purchase any securities.

This announcement is not for distribution into the United States, Canada, Japan,
Australia, the Republic of Ireland or the Republic of South Africa or any other
jurisdiction where its distribution would constitute a violation of the relevant

laws of such jurisdiction. Neither the Cross Shore Shares nor the Cross Shore
Warrants have been registered under the United States Securities Act of 1933, as
amended, or under the applicable securities laws of Canada, Japan, Australia,
the Republic of Ireland or the Republic of South Africa. Accordingly (subject to
certain exceptions), neither the Cross Shore Shares nor the Cross Shore Warrants
may, directly or indirectly, be offered or sold within the United States,

Canada, Japan, Australia, the Republic of Ireland or the Republic of South
Africa or to or by any national, resident or citizen of such countries. The
distribution of the Readmission Document in other jurisdictions may be
restricted by law and therefore persons into whose possession the Readmission
Document comes should inform themselves about and observe any such restrictions.
Any failure to comply with these restrictions may constitute a violation of the
securities law of any such jurisdictions.

Arbuthnot Securities Limited, which is authorised and regulated in the United
Kingdom by the Financial Services Authority, is acting as nominated adviser and
UK broker to the Company in connection with Re-admission. Its responsibilities
as the Company's nominated adviser under the AIM Rules are owed solely to the
London Stock Exchange and are not owed to the Company or to any Director or
Proposed Director or to any other person.

Arbuthnot Securities Limited is acting exclusively for the Company and for no
one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their clients or for providing advice in

relation to the contents of this announcement or the Re-admission. No
representation or warranty, express or implied, is made by Arbuthnot Securities
Limited as to the contents of this announcement. The information contained in
this announcement is not intended to inform or be relied upon by any subsequent
purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and
accordingly no duty of care is accepted in relation to them.

The Directors and Proposed Directors of Cross Shore Acquisition Corporation
accept responsibility, individually and collectively, for the information
contained in this announcement and for compliance with the AIM Rules. To the

best of the knowledge and belief of the Directors and Proposed Directors, who
have taken all reasonable care to ensure that such is the case, the information
contained in this announcement is in accordance with the facts and does not omit
anything likely to affect the import of such information.


END




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCOKOKDCBKDNFD